NCT02753803 - Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 27, 2016

Primary Completion Date

October 19, 2016

Study Completion Date

March 10, 2017

Conditions

Type 2 Diabetes

Interventions

DRUG

Evogliptin, Pioglitazone, Evogliptin+Pioglitazone

Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD

DRUG

Pioglitazone, Evogliptin, Evogliptin+Pioglitazone

Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD

DRUG

Evogliptin, Evogliptin+Pioglitazone, Pioglitazone

Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD

DRUG

Pioglitazone, Evogliptin+Pioglitazone, Evogliptin

Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD

DRUG

Evogliptin+Pioglitazone, Evogliptin, Pioglitazone

Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD

DRUG

Evogliptin+Pioglitazone, Pioglitazone, Evogliptin

Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD

Trial Locations (1)

Clinical Trials Center, Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY